Showing 7031-7040 of 9134 results for "".
- Cynosure's SculpSure Cleared for Back, Inner and Outer Thighshttps://practicaldermatology.com/news/cynosures-sculpsure-cleared-for-back-inner-and-outer-thighs/2458155/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen an
- Some Hair Products May Up Breast Cancer Risk in Certain Womenhttps://practicaldermatology.com/news/some-hair-products-may-up-breast-cancer-risk-in-some-women/2458156/Use of hair dyes may increase risk for breast cancer among certain women, new research suggests. Specifically, dark brown or black hair dye was associated with a 51 percent increased overall risk of developing breast cancer among African American women, and a 72 percent increased risk of
- FDA Cracks Down on Sonar For Distributing Unapproved Derm Drugshttps://practicaldermatology.com/news/fda-cracks-down-on-sonar-for-distributing-unapproved-derm-drugs/2458153/U.S. District Judge Kathleen M. Williams for the Southern District of Florida entered a consent decree of permanent injunction between the United States and Stratus Pharmaceuticals Inc. of Miami, Florida, Sonar Products Inc. of Carlstadt, New Jersey an
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- HED Research Fuels Understanding of Male Pattern Baldnesshttps://practicaldermatology.com/news/hed-research-fuels-understanding-of-male-pattern-baldness/2458162/The origins of hypohidrotic ectodermal dysplasia (HED) may help researchers get a better handle on the genetic underpinnings of common hair disorders. The findings appear in Nature Communications. About one in 5,000 to 10,000 people are thought to have HED, although this
- Retailers Charge Women More Than Men for Minoxidilhttps://practicaldermatology.com/news/retailers-charge-women-more-than-men-for-minoxidil/2458163/Women pay an average of 40 percent more than men for minoxidil foams, according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania in JAMA Dermatology</
- FDA Clears Clarify Medical Core Technology for At-home UVB Phototherapyhttps://practicaldermatology.com/news/fda-clears-clarify-medical-core-technology-for-at-home-uvb-phototherapy/2458165/The US Food and Drug Administration has cleared the Clarify Medical Phototherapy System for marketing, and the new smart, at-home UVB phototherapy system will be available to patients with chronic skin diseases in November. Clarify’s proprie
- PFD Patch Improves Laser Tattoo Removal Experiencehttps://practicaldermatology.com/news/pfd-patch-improves-laser-tattoo-removal-experience/2458170/Using a perfluorodecalin (PDF) patch during tattoo removal treatment may make the process quicker, safer and more tolerable, finds a new study in Lasers in Surgery and Medicine (LSM). The study was selected a
- Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commercehttps://practicaldermatology.com/news/sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce/2458174/Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary,